Introduction {#cesec10}
============

Hip replacement is a successful and cost-effective elective surgical intervention that is widely used to treat disabling joint pain, mainly caused by osteoarthritis. Some patients experience complications and one of the most severe is prosthetic joint infection (PJI),[@bib1] which is most commonly caused by coagulase-negative staphylococcus or *Staphylococcus aureus*.[@bib2] Although uncommon, PJI is devastating and leads to severe pain, poor function, reduced quality of life, and even death.[@bib1], [@bib3] The treatment burden is high for patients and health-care systems.[@bib4] Revision surgery is usually required and is complex, protracted, and associated with further complications.[@bib5], [@bib6] A large rise in the number of primary hip replacements is predicted[@bib7] and a proportionate rise in the number of patients requiring revision for PJI is expected.[@bib8] In England and Wales alone, over 1000 revision procedures are performed annually because of PJI of the hip.[@bib9]

Research in context**Evidence before this study**Prosthetic joint infection (PJI) is a devastating complication after hip replacement. In a systematic review published in 2016, we searched MEDLINE, Embase, Web of Science, and The Cochrane Library databases from inception up to Sept 1, 2015, using a registered protocol (PROSPERO: CRD42015023485) to identify the role of patient characteristics on the risk of developing PJI. Our search strategy combined terms related to exposures (eg, "risk factor", "body mass index", "comorbidity") with those related to outcomes (eg, "periprosthetic joint infection", "prosthetic joint infection", "deep prosthetic infection", "deep infection", "deep surgical site infection"). Longitudinal studies that reported on the associations of any patient factors with PJI after primary or revision total arthroplasty, who had at least 12 months of follow-up and who had a Newcastle-Ottawa Scale score of more than 5 were eligible. 512 508 hip replacements were pooled and showed that male sex, high body-mass index (BMI), steroid use, diabetes, rheumatoid arthritis, congestive heart failure, depression, and smoking and alcohol intake are each associated with an increased risk of PJI. The published literature was limited by short-term postoperative follow-up, variably adjusted data which did not enhance consistent comparison, substantial heterogeneity between contributing studies, and by not disentangling factors associated with early onset of PJI caused by the primary intervention from factors associated with later onset resulting from haematogenous spread. Older reviews had investigated the role of surgical intervention and health-care setting factors on the risk of revision for PJI but were also limited by the size of the studied samples, infected cases, short postoperative follow-up (≤12 months), and between study heterogeneity.Repeating the search on March 19, 2018, we identified two registry studies and a meta-analysis published since our previous review. Registry studies from Denmark and New Zealand observed increased risk of PJI in men, older patients, those with a high BMI, and those with rheumatoid arthritis. The meta-analysis showed weak evidence of reduced risk of PJI for non-metallic bearing surfaces. The authors highlighted the need for larger studies with adjustment for confounders.**Added value of this study**This study investigated the overall and postoperative period-specific effects of patient, surgical, and health system factors on the risk of revision for PJI, with a single dataset of 623 053 primary hip replacements in which patients were followed up for up to 11 years. Considering patient characteristics, this work corroborates the previous findings of our review and identifies other factors such as younger age, chronic pulmonary disease, liver disease, and dementia that are associated with an increased risk of PJI. Surgical factors, including indication for the primary surgery, surgery type, the lateral surgical approach, and non-ceramic bearing surfaces, were associated with an increased risk of PJI. We identified no effects or only small effects for surgeon and hospital volume or surgeon grade. More importantly, we identified that these factors have a different effect according to the postoperative period considered, with comorbidities such as dementia influencing early revision for PJI and liver diseases influencing long-term revision. The effect of bearing surfaces also varied according to the period considered but factors, such as age or BMI, increased the risk during all postoperative periods.**Implications of all the available evidence**The risk of revision for PJI after primary hip replacement is multifactorial, mainly driven by patient and surgical level factors with time-varying effects. The modifiable factors identified in this study should be considered by clinicians in their practice to develop targeted interventions and propose beneficial modulation of some of these factors. Of equal importance is for clinicians to consider the non-modifiable factors and the factors that exhibit time-specific effects on the risk of PJI, to counsel patients appropriately preoperatively.

Identification of individuals at high risk of PJI helps to inform the development of preventive strategies and optimise the detection of PJI. The risk of developing PJI is influenced by non-modifiable and modifiable patient, surgical, and health-care characteristics. In our systematic review[@bib10] of patient risk factors for PJI, we identified male sex, smoking, increasing body-mass index (BMI), steroid use, previous joint surgery, and comorbidities, such as diabetes, rheumatoid arthritis, and depression. Limitations of this review included short-term follow-up, pooled estimates based on variably adjusted data, and evidence of substantial heterogeneity between study settings. These limitations are also applicable to other systematic reviews of surgical and health-care system factors associated with revision for PJI.[@bib11], [@bib12]

Given these limitations, large-scale cohort studies are needed with adequate power to provide evidence on the nature and magnitude of the associations of potential risk factors for PJI. It is important to disentangle factors associated with early onset of PJI, which are likely to be the consequence of the primary intervention, from factors associated with later onset, which are more likely to result from haematogenous spread.[@bib6]

We aimed to assess the overall and postoperative period-specific associations of patient, surgical, and health-care setting factors with the risk of revision due to PJI in prospectively collected observational data of 623 253 primary total hip replacements performed in England and Wales.

Methods {#cesec20}
=======

Study design and participants {#cesec30}
-----------------------------

In this observational cohort study, we report analyses of data for England and Wales from the National Joint Registry (NJR) for England, Wales, Northern Ireland, and the Isle of Man between April 1, 2003, and Dec 31, 2014.

NJR data were linked to Hospital Episode Statistics and Patient Episode Database for Wales to obtain data on inpatient and day case admissions. Data from the Office for National Statistics were linked to obtain the date of death.

We included all patients who had a primary hip replacement between April 1, 2003, and Dec 31, 2013, in the study. Patient consent was obtained for data collection and linkage by the NJR. According to the National Health Service Health Research Authority, separate consent and ethical approval were not required for this study.

Procedures {#cesec40}
----------

We analysed primary hip replacements performed between April 1, 2003, and Dec 31, 2013, and revision procedures due to PJI that occurred after the primary replacement between April 1, 2003, and Dec 31, 2014. The reason for revision was recorded by clinicians at the time of the revision procedure and reflected a clinical judgment sufficient to lead the surgeon to perform an invasive procedure tailored to tackle a PJI. The diagnosis and treatment strategy for PJI was at the discretion of the surgeon and treating unit and was reflective of contemporary practice over the study period, with raised inflammatory markers, joint specific symptoms, sinuses, and positive microbiological cultures[@bib13] being common diagnostic features over that period.

Each patient who had a primary hip replacement was followed up for a minimum of 12 months until the end of the observation period (Dec 31, 2014) or until the date of revision for PJI, revision for another indication, or death. Revisions for PJI included debridement and implant retention with modular exchange, a single or a two-stage revision procedure.[@bib14]

We considered the patient characteristics age, sex, ethnicity, BMI, American Society of Anaesthesiologists (ASA) grade, and comorbidities. We obtained data for ethnicity and comorbidities from the Hospital Episode Statistics records. We used ICD-10 codes to classify comorbidities for which patients had been admitted to hospital in the 5 years preceding their primary operation ([appendix](#sec1){ref-type="sec"}).[@bib15]

We considered surgical factors such as indication for surgery, anaesthesia type, thromboprophylaxis regime, surgical approach, hip replacement type, bearing surface, use of bone graft, and occurrence of intraoperative complications.

We considered health system factors such as hospital type, funding stream, country, operating surgeon grade, consultant involvement, and volume of hip surgeries (categorised into quartiles) performed by the hospital, operating surgeon and surgeon in charge of the procedure in the preceding 12 months.

Statistical methods {#cesec50}
-------------------

We first investigated the associations between the risk factors and risk of revision for PJI across the overall follow-up period. We used Poisson multilevel models accounting for clustering at unit level (random intercept). Clustering at surgeon level was negligible and therefore ignored.

PJI management varies according to the time since the primary procedure and onset of infection. Early onset of PJI within 24 months of primary procedure is generally considered to result from the primary intervention. Later onset of PJI is more likely to be due to haematogenous spread. For patients with early post-operative or acute haematogenous PJI and a short duration of symptoms, debridement, modular exchange, and implant retention rather than full revision are appropriate.[@bib6] Therefore, we reinvestigated the associations over several at-risk postoperative periods: 0--3 months, 3--6 months, 6--12 months, 12--24 months, and more than 24 months. We split each patient\'s at-risk period (time elapsed between their primary procedure and endpoint) according to the time spent in each of these periods and we assigned the revision for PJI status (revised for PJI or not) to the relevant period. We used a piece-wise exponential multilevel model with period-specific effects to assess these associations---ie, their rate ratios (RR) and 95% CIs across these time-periods.[@bib16], [@bib17] We did analyses by running MLwiN from Stata 14.1 (StataCorp LP, TX, USA) using Markov Chain Monte Carlo methods.[@bib18] To account for test multiplicity, we derived adjusted p values using Simes\' false discovery rate testing controlling procedure.[@bib19], [@bib20] To be confident that 95% of the effects tested were not due to chance, we only discussed evidence of association for adjusted p value of 0·05 or lower.

We did the analyses on the overall sample for all exposures except for ethnicity and comorbidities, which we investigated in the 495 456 patients operated on in England with a record of hospital admission in HES but not in PEDW, and no evidence of residency outside England ([appendix](#sec1){ref-type="sec"}). We adjusted the regressions for age, sex, ASA grade, and BMI. BMI is an important risk factor for PJI but has substantial missing data in the NJR (47%), partly because it was not included as a variable in the early data collection forms. We used a multiple imputation strategy to impute BMI, assuming that data were missing at random, using a Gaussian normal regression imputation model with the factors age, sex, and ASA used as covariates, and the log of the observed event or censoring time and revision for PJI status. Due to the computational time required by each multilevel piece-wise model, we computed only five imputations and combined regression estimates by Rubin\'s rules. Unadjusted and adjusted models without BMI are available on request. To avoid overadjustment, we did not adjust models investigating the effect of comorbidities for ASA grade, a proxy indicator of comorbid profile.

Role of the funding source {#cesec60}
--------------------------

The National Institute for Health Research had no role in study design, data collection analysis, interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Results {#cesec70}
=======

623 253 primary hip procedures were done in 460 different surgical units with a median (IQR) of 1050 (460--1940) per unit. Baseline study sample characteristics are presented in [figure 1](#fig1){ref-type="fig"} and the [table](#tbl1){ref-type="table"}. 2705 primary procedures were subsequently revised for an indication of PJI after a median (IQR) follow-up of 4·6 years (2·6--7·0); 14% (n=372) of these within 3 months, 8% (n=204) in 3--6 months, 14% (n=374) in 6--12 months, 23% (n=612) in 12--24 months, and 42% (n=1143) beyond 24 months from the primary procedure. The mean patient age was 68 years (SD 11). The sample is presented by time periods in the [appendix](#sec1){ref-type="sec"}. In 523 (27%) of the 1959 two-stage revision procedures performed for PJI, only a second stage procedure was recorded in the NJR. Patients with incompletely registered two-stage procedures did not differ from those with complete procedures and their time to first-stage procedure was estimated ([appendix](#sec1){ref-type="sec"}).Figure 1Description of the sampleHES=Hospital Episode Statistics for England. PEDW=Patient Episode Database for Wales. \*Only data for England and Wales were considered; data collection for Northern Ireland started Feb 2, 2013, and primary revision procedures could not be considered due to their limited number and restricted follow-up. Data collection for the Isle of Man started on July 1, 2015, after the endpoint of this study and were not considered. †As recorded in HES for the 5 years preceding the primary hip replacement.TableSample description and incidence rates**Patients, nPerson-yearsCases, nIncidence per 1000 person-years (95% CI)Sex**Female372 2561 849 69112430·67 (0·64--0·71)Male250 9971 237 17014621·18 (1·12--1·24)**Age, years**\<60131 803688 0007391·07 (1·00--1·15)60--69191 128977 9639420·96 (0·90--1·03)70--79210 3871 033 8507820·76 (0·70--0·81)≥8089 935387 0492420·63 (0·55--0·71)**Ethnicity**White469 1292 256 67523081·02 (0·98--1·07)Black African origin285513 152120·91 (0·47--1·59)South Asian1605722360·83 (0·30--1·81)Other and mixed323514 405140·97 (0·53--1·63)Unclear18 63296 433250·26 (0·17--0·38)Unavailable[\*](#tbl1fn1){ref-type="table-fn"}127 797698 9723400·49 (0·44--0·54)**Body-mass index, kg/m^2^**\<2571 584297 6862720·91 (0·81--1·03)25--29·9133 037557 8265801·04 (0·96--1·13)≥30125 856517 2789411·82 (1·70--1·94)Missing292 7761 714 0729120·53 (0·50--0·57)**American Society of Anaesthesiologists grade**1114 367657 0594820·73 (0·67--0·80)2418 3352 036 02217720·87 (0·83--0·91)3--590 551393 7804511·15 (1·04--1·26)**Chronic pulmonary disease**No433 0032 127 27020640·97 (0·93--1·01)Yes62 453260 6183011·15 (1·03--1·29)Unavailable[\*](#tbl1fn1){ref-type="table-fn"}127 797698 9723400·49 (0·44--0·54)**Diabetes**No453 0572 209 50721200·96 (0·92--1·00)Yes42 399178 3812451·37 (1·21--1·56)Unavailable[\*](#tbl1fn1){ref-type="table-fn"}127 797698 9723400·49 (0·44--0·54)**Dementia**No493 3822 381 19823550·99 (0·95--1·03)Yes20746690101·49 (0·72--2·75)Unavailable[\*](#tbl1fn1){ref-type="table-fn"}127 797698 9723400·49 (0·44--0·54)**Liver disease**No491 4302 372 88323270·98 (0·94--1·02)Yes402615 005382·53 (1·79--3·48)Unavailable[\*](#tbl1fn1){ref-type="table-fn"}127 797698 9723400·49 (0·44--0·54)**Congestive heart failure**No484 7482 346 96023070·98 (0·94--1·02)Yes10 70840 928581·42 (1·08--1·83)Unavailable[\*](#tbl1fn1){ref-type="table-fn"}127 797698 9723400·49 (0·44--0·54)**Connective tissue and rheumatic disease**No473 5942 292 73322510·98 (0·94--1·02)Yes21 86295 1561141·20 (0·99--1·44)Unavailable[\*](#tbl1fn1){ref-type="table-fn"}127 797698 9723400·49 (0·44--0·54)**Cancer**No473 0462 299 17122620·98 (0·94--1·03)Non-metastatic cancer18 51177 688851·09 (0·87--1·35)Metastatic cancer389911 030181·63 (0·97--2·58)Unavailable[\*](#tbl1fn1){ref-type="table-fn"}127 797698 9723400·49 (0·44--0·54)**Cerebrovascular disease**No485 5082 348 22023290·99 (0·95--1·03)Yes994839 668360·91 (0·64--1·26)Unavailable[\*](#tbl1fn1){ref-type="table-fn"}127 797698 9723400·49 (0·44--0·54)**Myocardial infarction**No481 9222 330 89423050·99 (0·95--1·03)Yes13 53456 995601·05 (0·80--1·36)Unavailable[\*](#tbl1fn1){ref-type="table-fn"}127 797698 9723400·49 (0·44--0·54)**Paraplegia and hemiplegia**No493 4152 379 41623510·99 (0·95--1·03)Yes20418472141·65 (0·90--2·77)Unavailable[\*](#tbl1fn1){ref-type="table-fn"}127 797698 9723400·49 (0·44--0·54)**Peptic ulcer disease**No488 9942 358 64223330·99 (0·95--1·03)Yes646229 247321·09 (0·75--1·54)Unavailable[\*](#tbl1fn1){ref-type="table-fn"}127 797698 9723400·49 (0·44--0·54)**Peripheral vascular disease**No485 7202 349 62423180·99 (0·95--1·03)Yes973638 265471·23 (0·90--1·63)Unavailable[\*](#tbl1fn1){ref-type="table-fn"}127 797698 9723400·49 (0·44--0·54)**Renal disease**No479 6162 337 54523110·99 (0·95--1·03)Yes15 84050 343541·07 (0·81--1·40)Unavailable[\*](#tbl1fn1){ref-type="table-fn"}127 797698 9723400·49 (0·44--0·54)**Osteoarthritis**No43 673189 2792491·32 (1·16--1·49)Yes579 5802 897 58224560·85 (0·81--0·88)**Fractured neck of femur**No610 6933 043 48326390·87 (0·83--0·90)Yes12 56043 378661·52 (1·18--1·94)**Previous hip infection**No622 5973 083 80626830·87 (0·84--0·90)Yes6563055227·20 (4·51--10·90)**Avascular necrosis**No607 3083 007 21425970·86 (0·83--0·90)Yes15 94579 6471081·36 (1·11--1·64)**Dysplasia or congenital dislocation**No613 7103 038 03626770·88 (0·85--0·92)Yes954348 825280·57 (0·38--0·83)**Inflammatory arthropathy**No614 1173 040 37226650·88 (0·84--0·91)Yes913646 489400·86 (0·61--1·17)**Surgical approach**Posterior337 1881 565 91312420·79 (0·75--0·84)Lateral257 4871 399 28713340·95 (0·90--1·01)Other28 578121 6611291·06 (0·89--1·26)**Procedure**Resurfacing36 503245 0851740·71 (0·61--0·82)Total hip replacement cemented229 0081 196 70210140·85 (0·80--0·90)Total hip replacement uncemented241 2781 104 19610740·97 (0·92--1·03)Total hip replacement other116 464540 8784430·82 (0·74--0·90)**Type of bearing**Metal-on-polyethylene367 2261 805 84315050·83 (0·79--0·88)Metal-on-metal68 761447 6095261·18 (1·08--1·28)Ceramic-on-polyethylene73 607328 1832520·77 (0·68--0·87)Ceramic-on-ceramic99 651428 6003420·80 (0·72--0·89)Ceramic-on-metal or metal-on-ceramic226310 553201·90 (1·16--2·93)Other11 74566 073600·91 (0·69--1·17)**General anaesthesia**No323 7101 532 20013170·86 (0·81--0·91)Yes299 5431 554 66113880·89 (0·85--0·94)**Nerve block anaesthesia**No558 9902 751 59124260·88 (0·85--0·92)Yes64 263335 2702790·83 (0·74--0·94)**Epidural anaesthesia**No568 4252 752 93824150·88 (0·84--0·91)Yes54 828333 9232900·87 (0·77--0·97)**Spinal anaesthesia used**No244 7161 302 91211800·91 (0·85--0·96)Yes378 5371 783 94915250·85 (0·81--0·90)**Thromboprophylaxis regimen**Chemical562 8842 691 00523630·88 (0·84--0·91)Non-chemical60 369395 8563420·86 (0·77--0·96)**Acetabulum bonegraft**No597 4932 958 90525880·87 (0·84--0·91)Yes25 760127 9561170·91 (0·76--1·10)**Femur bonegraft**No618 4073 062 17426670·87 (0·84--0·90)Yes484624 687381·54 (1·09--2·11)**Intraoperative event**No615 8743 053 56226630·87 (0·84--0·91)Yes737933 299421·26 (0·91--1·70)**Place of surgery**England588 0862 914 43925390·87 (0·84--0·91)Wales35 167172 4221660·96 (0·82--1·12)**Funding**NHS506 7272 393 63621720·91 (0·87--0·95)Independent90 650500 7383540·71 (0·64--0·78)Unspecified25 876192 4871790·93 (0·80--1·08)**Grade of operating surgeon**Consultant526 7892 599 22522530·87 (0·83--0·90)Other48 598253 9482150·85 (0·74--0·97)**Consultant involvement**Operating526 7892 599 22522530·87 (0·83--0·90)Assisting33 262158 3231631·03 (0·88--1·20)Not involved63 202329 3122890·88 (0·78--0·98)**Total volume (operating surgeon) of hip replacements performed in previous 12 months**≤28164 527928 5048360·90 (0·84--0·96)29--63158 385797 3487520·94 (0·88--1·01)64--148153 734718 3595830·81 (0·75--0·88)\>148146 607642 6495340·83 (0·76--0·90)**Total volume (surgeon in charge) of hip replacements performed in previous 12 months**≤41165 921949 3318280·87 (0·81--0·93)42--84158 134780 7696820·87 (0·81--0·94)85--148152 186717 5236110·85 (0·79--0·92)\>148147 012639 2385840·91 (0·84--0·99)**Total volume (hospital) of hip replacements performed in previous 12 months**≤143160 375960 0287890·82 (0·77--0·88)144--256158 020799 1146590·82 (0·76--0·89)257--406154 586671 9955810·86 (0·80--0·94)\>406150 272655 7246761·03 (0·95--1·11)[^2]

RR of PJI revision surgery are presented in [appendix](#sec1){ref-type="sec"}.

Men were at higher risk of revision for PJI in all time periods than women ([figure 2](#fig2){ref-type="fig"}). Over the entire follow-up, the risk was lower for patients older than 70 years than for patients younger than 60 years. However, this reduced risk was only observed after the first 6 months ([appendix](#sec1){ref-type="sec"}). BMI of 30 kg/m^2^ or higher was associated with an increased risk compared with BMI of less than 25 kg/m^2^. Patients with an ASA grade of 2 or higher were at greater risk than healthy patients ([table](#tbl1){ref-type="table"}). This was particularly evident during the first 6 months ([appendix](#sec1){ref-type="sec"}).Figure 2Risk factors of revision for prosthetic joint infection for the overall postoperative period, 2003--13Reference category in parentheses. BMI=body-mass index. ASA=American Society of Anaesthesiologists. THR=total hip replacement. MoM=metal-on-metal. MoP=metal-on-polyethylene. CoP=ceramic-on-polyethylene. CoC=ceramic-on-ceramic. CoM=metal-on-ceramic. \*Adjusted p value \<0·05 (details in the [appendix](#sec1){ref-type="sec"} alongside the rate ratios and 95% CIs).

Patients with a pre-existing history of chronic pulmonary disease, diabetes, liver disease, congestive heart failure, or connective tissue and rheumatologic diseases had a higher risk than did those without pre-existing history of these diseases ([figure 2](#fig2){ref-type="fig"}). Patients with diabetes or dementia were at increased risk of early revision for PJI ([figure 3](#fig3){ref-type="fig"}). Patients with liver disease were only at high risk beyond 24 months. No time-specific effect was observed for other comorbidities ([appendix](#sec1){ref-type="sec"}).Figure 3Risk factors of revision for prosthetic joint infection for the first 3 postoperative monthsReference category in parentheses. BMI=body-mass index. ASA=American Society of Anaesthesiologists. THR=total hip replacement. MoM=metal-on-metal. MoP=metal-on-polyethylene. CoP=ceramic-on-polyethylene. CoC=ceramic-on-ceramic. CoM=metal-on-ceramic. \*Adjusted p value \<0·05 (details in the [appendix](#sec1){ref-type="sec"} alongside the rate ratios and 95% CIs).

The risk varied according to the indication for the primary procedure. Patients operated on for osteoarthritis were less likely to be revised for PJI than those without osteoarthritis. Patients operated on for a fractured neck of femur, avascular necrosis ([figure 2](#fig2){ref-type="fig"}), or history of previous infection of the operated joint were at increased risk ([table](#tbl1){ref-type="table"}; [appendix](#sec1){ref-type="sec"}). A fractured neck of the femur was only associated with an increased risk of early revision for PJI ([figure 3](#fig3){ref-type="fig"}).

Operations done via a posterior surgical approach had the lowest risk of revision for PJI compared with other surgical approaches ([figure 2](#fig2){ref-type="fig"}). The surgical approach did not influence the early risk of revision for PJI ([figure 3](#fig3){ref-type="fig"}), but from 3 months onwards patients who had undergone a lateral approach were at higher risk ([appendix](#sec1){ref-type="sec"}).

Patients who had a primary hip resurfacing were at lower risk of revision for PJI ([figure 2](#fig2){ref-type="fig"}), but this lower risk was not evident in the first 3 postoperative months ([figure 3](#fig3){ref-type="fig"}). In the early postoperative period, patients who had undergone an uncemented, hybrid, or reverse hybrid total hip replacement (THR other, [figure 3B](#fig3){ref-type="fig"}) were at higher risk than those with cemented implants but from 3 to 24 months, they were at lower or similar risk ([appendix](#sec1){ref-type="sec"}). Further analysis showed a higher early risk of revision in patients with hybrid implant THRs (RR~\<3mth~ 1·7, 95% CI 1·2--2·3) than in those with reverse hybrid implants (0·9, 0·4--2·0).

The risk of revision for PJI was also influenced by the type of bearing surfaces and this varied according to the time period. In the early postoperative period, no differences were observed ([figure 3](#fig3){ref-type="fig"}). Between 3 and 24 months, metal-on-metal THRs had a lower or similar risk than did metal-on-polyethylene THRs; beyond 24 months, the risk was higher for metal-on-metal ([appendix](#sec1){ref-type="sec"}). When the model was further adjusted for the type of surgery (resurfacing and THR cemented or not) the higher revision risk for PJI in the metal-on-metal group was identified earlier, from 12 months postoperation onwards (RR~12--24mth~ 1·8, 95% CI 1·3--2·3; RR~\>24mth~ 2·2, 1·8--2·6). Ceramic-on-ceramic and ceramic-on-polyethylene surfaces were associated with a lower risk of long-term revision (from 12 months for ceramic-on-ceramic and 24 months for ceramic-on-polyethylene postoperation onwards) than metal-on-polyethylene bearings, which also had a higher risk of long-term revision for PJI ([appendix](#sec1){ref-type="sec"}).

Little or no difference in the risk of revision for PJI was found for the choice of anaesthetic technique, thromboprophylaxis regime, use of acetabular bone graft, or experience of intraoperative complication ([Figure 2](#fig2){ref-type="fig"}, [Figure 3](#fig3){ref-type="fig"}; [appendix](#sec1){ref-type="sec"}) Patients who received a femoral bone graft during the primary procedure were at higher risk of PJI with no evidence of a postoperative period-specific effect ([figure 3](#fig3){ref-type="fig"}; [appendix](#sec1){ref-type="sec"}).

The risk of revision for PJI was not different between Wales and England nor between the funding sources of the primary procedure ([figure 2](#fig2){ref-type="fig"}).

Revision for PJI was not influenced by the grade of the operating surgeon and the presence or absence of a consultant surgeon during surgery ([figure 2](#fig2){ref-type="fig"}).

Operating surgeons who had performed over 63 procedures in the 12 months preceding the primary surgery were weakly associated with a lower risk of revision for PJI than surgeons with a lower volume ([figure 2](#fig2){ref-type="fig"}). This pattern was inconsistent between time-periods and did not influence the early risk of revision for PJI ([figure 3](#fig3){ref-type="fig"}; [appendix](#sec1){ref-type="sec"}). The volume of all hip procedures done by the surgeon in charge of the surgery did not affect the risk of revision ([figure 2](#fig2){ref-type="fig"}). The risk of revision for PJI was higher in the first 3 months after primary surgery in hospitals that had performed over 255 hip procedures in the 12 months preceding the primary surgery than with hospitals with a small volume of activity ([figure 3](#fig3){ref-type="fig"}). No specific difference in the rate ratios were found beyond this period or for units with lower volumes of hip procedures ([appendix](#sec1){ref-type="sec"}).

Discussion {#cesec80}
==========

At the patient level, men, younger patients, and those with high BMI or high ASA grades had an increased risk of revision for PJI. Comorbidities that increased the risk of revision for PJI included chronic pulmonary disease, diabetes, dementia, liver disease, congestive heart failure, and connective tissue or rheumatic diseases. These comorbidities and elevated BMI can potentially be optimised before surgery. A targeted preoperative intervention for male patients with high BMI and specific comorbidities seems particularly relevant.

At the surgical level, patients undergoing THR for fractured neck of femur or avascular necrosis were at higher risk of revision for PJI. Patients with a fracture are different to those who have conditions such as osteoarthritis, generally being older with a higher risk of mortality.[@bib21] Conditions that cause avascular necrosis, such as steroid use or irradiation, cause immunosuppression and also predispose towards PJI. The markedly higher risk in those with historical infection of the hip is novel, though unsurprising, and might be due to quiescent bacteria or other immune conditions that predispose to PJI. Lateral surgical approach and use of femoral bone graft also increased the risk. The increased risk with the lateral surgical approach is a novel finding that we postulate is due to increased tissue damage and bleeding caused by violating the abductor mechanism. Previous studies have suggested that the lateral approach is associated with more bleeding,[@bib22] worse patient related outcomes,[@bib23] and higher mortality.[@bib24] Approximately one third of hip replacements undertaken in England and Wales in 2016, still utilised this approach---although its use is declining.[@bib21] Early revision for PJI was higher in those receiving uncemented than cemented implants independent of bearing surface. At later time points, the risk was lower for uncemented THRs and resurfacings. This might reflect an initial protective effect of antibiotic impregnated bone cement. Long-term risk was higher in metal-on-metal bearings, possibly due to the soft tissue destruction associated with these implants,[@bib25] and was lower in bearings that included ceramic heads, which is concordant with a report[@bib26] from the Medicare population in the USA. In this Medicare population, ceramic bearings were used in younger and healthier patients. Our study adjusted for age and health status, which should mitigate the effects of any selection bias. A meta-analysis[@bib27] also showed weak evidence of reduced risk of PJI for ceramic bearing surfaces.

Factors at the health-care system level appear to be less important with no marked sustained associations across the time periods studied.

Consistent with previous studies,[@bib10], [@bib12], [@bib28] we observed higher risk in men and patients with high BMI. Contrary to previous findings,[@bib10], [@bib12] younger patients were at higher risk, which could reflect the increased follow up in our study. Older patients could be at lower risk due to a propensity to non-operative management of PJI in this group. Smoking has previously been identified as a risk factor,[@bib10], [@bib29] and although we did not have information on smoking habit, the surrogate comorbidity of chronic pulmonary disease was associated with increased risk. Evidence of an association between alcohol intake and increased risk has been inconsistent.[@bib30], [@bib31] We observed higher risk in patients with liver disease, but this might represent several pathologies. Our study corroborates the previous findings[@bib10], [@bib30], [@bib32] of increased risk in patients with diabetes, rheumatoid arthritis, and congestive heart failure. We have shown for the first time that dementia is associated with an increased risk of early revision for PJI, which might reflect the high prevalence of other comorbidities in these patients.

The current study has several strengths. To our knowledge, this is the largest and most comprehensive investigation of several patient, surgical, and health-care related factors and their risk for revision for PJI of the hip. We used a large-scale cohort design comprising more participants (n=623 253) than those of the most up-to-date review on the topic (n=512 508 hip and knee replacements).[@bib10] Other strengths include the longer term follow-up of the cohort (median 4·6 years) and cutting-edge statistical analyses, which include the assessment of the effects of these potential risk factors at time-specific periods.

Our study has some limitations. Although pros-pectively collected, our data is observational and we can only draw inferences on the nature and magnitude of the associations but cannot establish causation. In the UK, no national gold standards have been agreed upon that are available to orthopaedic surgeons to diagnose PJI. As such, the reported indication of PJI in the NJR might vary between units but is reflective of contemporary practice with raised inflammatory markers, joint specific symptoms, sinuses, and positive microbiological cultures being used to diagnose PJI.[@bib13] The PJI diagnosis reflects a clinical judgment sufficient to lead the surgeon to conduct a very severe and invasive procedure tailored to tackle a PJI. Issues relating to under-reporting of revision for PJI, and thus potentially lower incidence estimates, are acknowledged.[@bib33] Linkage of the NJR data to microbiology data could reduce any misdiagnoses of PJI but has proven to be of limited generalisability with 12% NJR linkage achievable.[@bib34]

The associations we have identified might vary with different causative pathogens, but unfortunately we do not have the data to explore this. Our findings should be considered as conservative estimates of the risk factors with the strongest effects. The investigations of the effect of comorbidities were limited to a subset of NJR patients linked to HES. This subset had higher ASA grades and therefore higher rate of revision for PJI than those excluded from these investigations, but they did not differ in terms of age, sex, BMI, or surgical characteristics, suggesting little evidence of differential selection bias. All other factors were investigated on the entire sample.

We have done appropriate modelling to adjust for known relevant confounders but residual confounding is still possible. We had no specific data on confounders, such as smoking and alcohol consumption, but have surrogate markers, such as chronic pulmonary disease and liver disease. BMI was not collected in the early years of the registry necessitating imputation of the data as with a previous study on this dataset.[@bib24] Competing risk due to revision for another cause or death, which in combination affected 55% of the primary hip replacements in the dataset during the period of observation, could not be accounted for in the modelling strategy. This was a pragmatic decision because we chose a strategy focusing on time-specific effects while accounting for the clustering nature of the data to disentangle the effect associated with surgical factors (likely to be more marked in the short-term to mid-term follow-up period) from those associated with health-risk behaviour (likely to be more marked in the mid-term to long-term follow-up period). This strategy was optimal because evidence supports non-proportional hazard rates. Finally, it was not possible to investigate any ethnic disparities in terms of revision for PJI due to the insufficient number of ethnic minority patients revised for PJI.

Preventive strategies for PJI largely focus on hygiene, use of protective equipment, management of care equipment and occupational exposure, and safe care of linen, the environment, and waste.[@bib35] Combinations of systemic antibiotics, antibiotic-impregnated cement, and conventional operating theatre ventilation are considered cost effective for preventing PJI.[@bib35] Identification of patient factors associated with increased need for revision for PJI can further guide the development of interventions and help target the provision of appropriate preventative care.

Using the largest longitudinal sample of primary hip replacements, we have shown several modifiable and non-modifiable factors to be associated with the risk of revision for a PJI after a primary hip replacement. For patients about to have hip replacement, identification of modifiable factors, use of targeted interventions, and beneficial modulation of some of these factors could be effective in reducing the incidence of PJI. It is important for clinicians to consider the non-modifiable factors, and the factors that exhibit time-specific effects on the risk of PJI, to counsel patients appropriately preoperatively.
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